Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
Abstract Background There is no consensus on the optimal initial treatment for polypoidal choroidal vasculopathy (PCV). Our study aimed to report the efficacy of repeated injections of intravitreal ranibizumab with or without photodynamic therapy for the treatment of PCV and to determine the possibl...
Main Authors: | Xiaoya Gu, Xiaobing Yu, Hong Dai |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-07-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12886-019-1156-4 |
Similar Items
-
Polypoidal Choroidal Vasculopathy: An Update on Therapeutic Approaches
by: Raymond L.M. Wong, et al.
Published: (2013-01-01) -
Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab
by: Zeynep Alkin, et al.
Published: (2016-12-01) -
Current management strategy of polypoidal choroidal vasculopathy
by: Christine P S Ho, et al.
Published: (2018-01-01) -
Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
by: Aditya Bansal, et al.
Published: (2017-01-01) -
Treatment Outcomes in Patients with Polypoidal Choroidal Vasculopathy
by: Mümin Hocaoğlu, et al.
Published: (2016-01-01)